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Background: Transcription factor Sp1 is multifaceted, with the ability to function as an oncogene or a tumor
suppressor, depending on the cellular context. We previously reported that Sp1 is required for the transcriptional
activation of the key oncogenes in nasopharyngeal carcinoma (NPC), including B-lymphoma mouse Moloney
leukemia virus insertion region 1 (Bmi1) and centromere protein H (CENPH), but the role of Sp1 and its underlying
mechanisms in NPC remained largely unexplored. The objective of this study was to investigate the cellular function
of Sp1 and to verify the clinical significance of Sp1 as a potential therapeutic target in NPC.
Methods: The levels of Sp1 in the normal primary nasopharyngeal epithelial cells (NPECs) and NPC cell lines were
analyzed by Quantitative Real-time RT-PCR (qRT-PCR) and Western blot. The location and expression of Sp1 in the
NPC tissues were detected by immunohistochemistry staining (IHC). The effect of Sp1 knockdown on the cell
proliferation, clonogenicity, anchorage-independent growth and the stem-cell like phenotype in NPC cells were
evaluated by MTT, flow cytometry, clonogenicity analysis and sphere formation assay.
Results: The mRNA and protein levels of Sp1 were elevated in NPC cell lines than in the normal primary NPECs.
Higher expression of Sp1 was found in NPC tissues with advanced clinical stage (P = 0.00036). Either inhibition of
Sp1 activity by mithramycin A, the FDA-approved chemotherapeutic anticancer drug or Sp1 silencing by two
distinct siRNA against Sp1 suppressed the growth of NPC cells. Mechanism analysis revealed that Sp1 silencing may
suppress cell proliferation, clonogenicity, anchorage-independent growth and the stem-cell like phenotype through
inducing the expression of p27 and p21, and impairing the expressions of the critical stem cell transcription factors
(SCTFs), including Bmi1, c-Myc and KLF4 in NPC cells.
Conclusions: Sp1 was enriched in advanced NPC tissues and silencing of Sp1 significantly inhibited cell
proliferation, clonogenicity, anchorage-independent growth and the stem-cell like phenotype of NPC cells,
suggesting Sp1 may serve as an appealing drug target for NPC.
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Nasopharyngeal carcinoma (NPC) is one of the lead-
ing malignancies in southern China and Southeast
Asia [1,2]. The annual incidence rate reaches 30 cases
per 100,000 people in the endemic regions, which
is about 25-fold higher than in the rest of the world
[1-3]. NPC shows familial clustering, resulting pre-
dominantly from inherited susceptibility [4]. Elevated
levels of serum Epstein-Barr virus (EBV)-related anti-
bodies, circulating and intratumoral EBV DNA were
consistently detected in NPC individuals, demonstrat-
ing that EBV infection is a strong risk factor for NPC
[5-7]. In addition, smoking and consumption of salt-
preserved foods have also been reported to be the
moderate risk factors for NPC [8,9]. Therefore, NPC is
a malignancy with a complex etiology involving both
genetic and environmental factors [1-3]. Although
radiotherapy or chemo-radiotherapy has been acknowl-
edged as standard treatment options, these treatments
induce a considerable incidence of acute mucosal and
hematologic toxicity [10-12]. Thus, it is urgent to iden-
tify the potential therapeutic agents for NPC.
Sp1 was identified as a transcription factor by bind-
ing to the promoters of its target genes and has been
postulated to play important roles in the regulation of
multiple critical biological functions, including cell
apoptosis [13] and growth [14], cycle progression [15],
purine/pyrimidine synthesis [16], metabolism [17],
angiogenesis [18,19] and metastasis [20,21]. Growing
evidence demonstrated Sp1 is abnormally expressed in
a variety of epithelial tumors originating from different
tissues, including breast [22], thyroid [23], pancreas
[24], stomach [25] and lung [26]. Deregulation of Sp1
may promote tumor development through regulating
transcription of genes, such as c-Myc [27], cyclin D1
[28], VEGF [29] and MMP9 [30]. In contrast, overex-
pression of Sp1 in highly invasive lung adenocarcin-
oma cells increases expression of E-cadherin and
inhibits metastasis [20]. Moreover, Sp1 induces apop-
tosis through cooperating with p53 [31]. Therefore,
Sp1 may serve as an oncogene or a tumor suppressor
in tumor development and deserved to be studied in
depth.
We previously identified Sp1 as an important tran-
scription factor for oncogenes in NPC, including B-
lymphoma mouse Moloney leukemia virus insertion re-
gion 1 (Bmi1) and centromere protein H (CENPH), but
the role of Sp1 in the development of NPC remains ob-
scure [32,33]. In the present study, we found the level of
Sp1 was elevated in advanced NPC tissues and silencing
of Sp1 significantly inhibited cell proliferation, clono-
genicity, anchorage-independent growth and the stem-
cell like phenotype of NPC cells, suggesting Sp1 as a po-
tential therapeutic target for NPC.Materials and methods
Reagents
The reagents used were as follows: rabbit polyclonal
antibodies against Sp1 (#07-645, Millipore, Temecula,
CA, USA), p27 (#60-645, Millipore), CDK4 (ab137818,
Abcam, Cambridge, MA, USA); mouse monoclonal anti-
bodies (mAb) against p21 (sc-6246, Santa Cruz, CA,
USA), α-tublin (T6199, Sigma-Aldrich, St Louis, MO,
USA), GAPDH (sc-32233, Santa Cruz). All other re-
agents were obtained from Sigma-Aldrich, unless other-
wise indicated.
Patients and tissue specimens
The paraffin-embedded NPC specimens (n = 76) were
obtained from Cancer Center of Sun Yat-sen University
in Guangzhou, People’s Republic of China. Written in-
formed consent was obtained from each patient, and the
study was approved by the Institute Research Ethics
Committee at the Cancer Center. The clinical character-
istics of the NPC patients were described in Table 1. All
cases were histologically confirmed.
Cell culture
Normal primary NPECs (NPECw and NPEC01) were
established as described previously [34], and cultured in
keratinocyte/serum-free medium (Invitrogen, Carlsbad,
CA, USA). The NPC cell lines (CNE2, HNE1, HONE1,
C666-1 and HK1) were cultured in RPMI 1640 (Invitro-
gen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (FBS; Hyclone, Logan, UT), and in a humidified
5% CO2 incubator at 37°C.
SiNRA transfection
The siRNA oligoribonucleotides were purchased from
Dharmacon (Rockford, USA) and Ribobio (Ribobio,
Guangzhou, China). The siRNAs targeting the
mRNA of human Sp1 [GenBank: NM_138473.2] was
denoted as siSp1-1# (L-026959-00-0003) and siSp1-
2# (siG0898155658). The negative control (NC) RNA
duplex for the siRNA was nonhomologous to any
human genome sequences, and was indicated as siNC (D-
001220-01-20). CNE2 and HNE1 cells (1 × 105) were
seeded on 6-well plates for 16 h, followed by transfection
with 50 nM of the RNA duplex and 5 μL of Lipofecta-
mine RNAiMAX (Invitrogen, Grand Island, NY, USA),
according to the manufacturer’s instructions. After 72 h,
cells were washed with PBS and harvested for further
experiments.
Quantitative real-time RT-PCR
Total RNA from NPC cell lines or tissue specimens was
extracted using the TRIzol reagent (Invitrogen, Grand
Island, NY, USA) according to the manufacturer’s instruc-
tions. Complementary DNA (cDNA) was synthesized from
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NKUC non-keratinizing undifferentiated carcinoma.
NKDC non-keratinizing differentiated carcinoma.
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(Invitrogen). The mRNA level was determined by
quantitative Real-time RT-PCR (qRT-PCR) using the
Power SYBR Green qPCR SuperMix-UDG (Invitrogen,
Grand Island, NY, USA) and was analyzed on an
ABIPrism-7500 Sequence Detector System (ABI, ap-
plied biosystems, USA). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) or β-actin was used as an
internal control. The primers are listed in Table 2.
Relative expression of the indicated gene was normal-
ized to GAPDH or β-actin expression, which yielded a
2-△△Ct value. All reactions were run in triplicate.Western blot
Western blot was performed as previously described
[32]. Briefly, cells were harvested and lysed in RIPA buf-
fer containing protein inhibitor cocktail (F. Hoffmann-
La Roche Ltd, Basel, Switzerland). The protein concen-
tration was determined by the BCA method (Pierce,
Rockford, IL). The protein (10 μg) was electrophoretic-
ally separated in 9 or 12% SDS polyacrylamide gels, and
transferred to polyvinylidene difluoride membranes
(Millipore). After probing with the indicated antibodies,
the signals were detected using enhanced chemilumines-
cence (ECL) (Amersham Pharmacia Biotech, Piscataway,
NJ). The same membranes were stripped and reprobed
with mouse monoclonal antibodies against GAPDH or
α-tubulin to confirm equal loading of the samples.
Immunohistochemical staining (IHC)
Immunohistochemical staining (IHC) was performed as
previously described [34]. Briefly, paraffin-embedded
samples were cut into 4 μm sections and placed on
polylysine-coated slides. Paraffin sections were baked for
2 h at 58°C, de-paraffinized in xylene, rehydrated
through graded ethanol, quenched for endogenous per-
oxidase activity in 0.3% hydrogen peroxide for 10 min,
and processed for antigen retrieval by high pressure
cooking in citrate antigen retrieval solution (pH = 6.0)
for about 5 min. Sections were incubated at 4°C over-
night with rabbit polyclonal antibodies against Sp1
(Millipore, 1:3200) in a moist chamber. Immunostaining
was performed using the Zymed Histostain TMPlus Kits
(Zymed, South San Francisco, CA, USA), which resulted
in a brown-colored precipitate at the antigen site. Subse-
quently, sections were counterstained with hematoxylin
(Zymed Laboratories, South San Francisco, CA) and
mounted in a non-aqueous mounting medium. All runs
included a no primary antibody control. The immuno-
histochemically stained tissue sections were scored sep-
arately by two pathologists blinded to the clinical
parameters. The staining intensity was scored as 0 (nega-
tive), 1 (weak), 2 (medium) or 3 (strong). Extent of stain-
ing was scored as 0 (0-10%), 1 (10-25%), 2 (26-50%) and
3 (51%-100%) according to the percentages of the posi-
tive staining areas in relation to the whole carcinoma
area. The product of the intensity and extent score was
used as the final staining score (0–9) for Sp1. Tumors
having a final staining score of < 4.5 were considered to
be low and those with score of ≥ 4.5 were considered to
be high.
MTT assay
Forty-eight hours after transfection with siSp1-1#, siSp1-
2# or siNC, CNE2 and HNE1 cells were plated in tripli-
cate at 2000 cells per well in 96-well plates and main-
tained in RPMI containing 10% FBS. At the indicated
Table 2 Sequences of primers
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dimethylthiazol-a-yl)-2, 5-diphenyl tetrazolium brom-
ide) was added to each well, and cells were incubated
for 4 h at 37°C. The media was then discarded, and
200 μl of DMSO was added to each well for 20 min at
RT to dissolve the precipitates. Absorbance was mea-
sured using the Spectramax M5 (Molecular Devices,
CA, USA) at a wavelength of 570 nm.Colony formation assay
Forty-eight hours after transfection with siSp1-1#, siSp1-
2# or siNC, CNE2 and HNE1 cells were plated in triplicate
at 200 cells per well in six-well plates and maintained in
RPMI containing 10% FBS for 10 days. Colonies were
fixed with methanol and stained with 0.1% crystal violet in
20% methanol, and then were photographed and counted.
All visible colonies were quantified.Anchorage-independent growth
Forty-eight hours after transfection with the indicated
RNA duplex, CNE2 and HNE1 cells (1 × 104) that were
suspended in 0.33% top agar (in RPMI with 10% FBS)
were plated onto 0.55% base agar (in RPMI with 5%
FBS) in six-well plates for 14 days. The colonies with the
diameter bigger than 10 μm were counted.Sphere formation assay
Forty-eight hours after transfection with the indicated
RNA duplex, CNE2 cell (5 × 102) that were suspended in
tumor sphere medium containing serum-free DMEM/F-
12, N2 supplement, 10 ng/mL human recombinant bFGF
and 10 ng/mL EGF were plated in six-well plates (ultra
low attachment surface) for 7 days. Colonies were
photographed at 200× magnification and were counted
at 40× magnification.Statistical analysis
All data analysis was conducted with GraphPad Prism
version 4.0 (GraphPad Software, San Diego, CA, USA)
and SPSS 16.0 (SPSS, Chicago, IL, USA). The results were
representative of at least three independent experiments.
Data were presented as the mean ± standard error of the
mean (SEM) obtained with triplicate samples. Analysis of
the differences between groups was determined with the
two-tailed Mann–Whitney test. A P-value of 0.05 was
used as the criterion of statistical significance.Results
High level of Sp1 correlates with tumor progression in
nasopharyngeal carcinoma
To explore the significance of Sp1 in the development of
nasopharyngeal carcinoma, the mRNA and protein levels
of Sp1 were first examined in the normal primary naso-
pharyngeal epithelial cells (NPECs) and NPC cell lines.
Both qRT-PCR and Western blot showed that the level
of Sp1 in the four NPC cell lines (HNE1, HONE1, CNE2
and C666-1) was obviously higher than the normal pri-
mary NPECs (NPECw and NPEC01) (Figure 1). The ex-
pression and subcellular localization of Sp1 in 76 NPC
tissues were then determined by immunohistochemistry.
As shown in Figure 2, Sp1 was expressed predominantly
in the nuclei of NPC cells of the tumor regions (T), but
demonstrated weak signal in the NPEC of the non-
tumor regions (N). In addition, Sp1 was present in some
infiltrating lymphocytes of both the non-tumor and
tumor regions of NPC patients. To evaluate the clinical
significance of Sp1 in nasopharyngeal carcinoma, the
correlation between Sp1 level and the clinical variations
was analyzed using χ2 test. As shown in Table 3, the ex-
pression of Sp1 was significantly associated with the
clinical stage (P = 0.00036), T (P = 0.002) and N (P =
0.034) classification. There was no significant correlation
Figure 1 Expression of Sp1 is higher in NPC cell lines than the
normal primary NPECs. Sp1 protein and mRNA levels were
analyzed by Western blot (A and B) and qRT-PCR (C) in the normal
primary NPECs (NPECw and NPEC01), and NPC cell lines (HNE1,
HONE1, CNE2 and C666-1). These results were reproducible in three
independent experiments and the representative immunoblots
were shown in A. Both the protein and mRNA levels of Sp1 were
normalized to GAPDH.
Figure 2 Expression of Sp1 in situ tumors of NPC patients. Sp1-
positive cells were stained brown and present in the nuclei of tumor
cells and some lymphocytes. Strong positive staining for Sp1 in NPC
cells of the tumor region (T) was marked as red arrow (lower left
panel), while negative or weak staining for Sp1 in NPEC of the
adjacent non-tumor region (N) was indicated as white arrow
(lower right panel). Representative images with low (100×, upper
panels) and high (400×, lower panels) magnification were shown.
Scale bar = 20 μm.
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classification as well as histologic classification in NPC
patients. These results suggested that the increase in
intratumoral Sp1-positive NPC cells was associated with
NPC progression.Knockdown of Sp1 suppresses the proliferation of NPC cells
To investigate the potential roles of Sp1 in tumorigenesis,
the effect of Sp1 on the cell growth was first evaluated.
CNE2 and HNE1 cells were cultured in the presence of
100 nM mithramycin A (MITA), a FDA-approved chemo-
therapeutic anticancer drug that inhibits transcriptional
activity of Sp1 by competitively binding to the Sp1-
binding sites. The cell viability was determined by MTT
on the indicated times. Compared with DMSO-treated
cells, the cell viability was significantly suppressed in
MITA-treated CNE2 and HNE1 cells (Figure 3A).
Next, we assessed the effect of Sp1 knockdown on the
cell growth of NPC cells. HNE1 and CNE2 cells were
transfected with the two distinct siRNA duplexes against
Sp1, and then subjected to Western blot. The level of Sp1
was nearly abolished in siSp1 transfectants (Figure 3B).
Compared to the control, siSp1 transfectants displayed
significantly lower proliferation, suggesting the growth-
promoting role of Sp1 in NPC cells (Figure 3C).
Knockdown of Sp1 suppressed the G1/S phase transition
and increased the expressions of p21 and p27
To assess whether cell cycle progression was involved in
Sp1-promoted cell growth, CNE2, HNE1 and HK1 cells
were transfected with the indicated RNA duplex for 48 h,
Table 3 Correlation between the clinical characteristics




≤ 45 18 (54.5%) 16 (37.2%) 0.165
> 45 15 (45.5%) 27 (62.8%)
Gender
Male 24 (72.7%) 31 (72.1%) 1.01
Female 9 (27.3%) 12 (27.9%)
Clinical stage
I-II 18 (54.5%) 6 (14%) 0.00036
III-IV 15 (45.5%) 37 (86.0%)
T classification
T1-T2 22 (66.7%) 13 (30.4%) 0.002
T3-T4 11 (33.3%) 30 (69.6%)
N classification
N0-N1 25 (75.8%) 22 (51.2%) 0.034
N2-3 8 (24.2%) 21 (48.8%)
Metastases
No 33 (100%) 41 (95.3%) 0.502
Yes 0 2 (4.7%)
Histological classification
NKUC 31 (93.9%) 43 (100%) 0.185
NKDC 2 (6.1%) 0
Fisher’s exact test
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distribution of initially asynchronous cells. Knockdown
of Sp1 showed a marked induction of G1 arrest in
CNE2, HNE1 and HK1 cells, whereas had no effect on
apoptosis as evaluated by sub-G1 peak (Figure 4A and B).
The G1/S-phase transition has been characterized as a
balance of cyclins, CDKs and Cip1 proteins. Cyclins
promote S phase, whereas p27 and p21 maintain cells
in G1 arrest. CDK4, p27 and p21 have been reported to
regulate the G1/S-phase transition and are potentially
regulated by Sp1 [35-37]. To study whether Sp1 pro-
motes cell cycle through the expression regulation of
these molecules in nasopharyngeal carcinoma, CNE2,
HNE1 and HK1 cells were transfected with siSp1 and
siNC for 48 h, followed by analysis for the levels of
Sp1, CDK4, p27 and p21. Either qRT-PCR or Western
blot demonstrated that Sp1 knockdown obviously up-
regulated the levels of p27 and p21, but had no effect
on the expression levels of CDK4 (Figure 4C and D),
indicating Sp1 knockdown blocked the G1/S transition
through induction of p27 and p21 in NPC cells.Knockdown of Sp1 suppressed clonogenicity and
anchorage-independent growth
We then analyzed the effect of Sp1 on the clonoge-
nicity and anchorage-independent growth of NPC
cells. CNE2 and HNE1 cells were transfected with the
indicated RNA duplex, and then allowed to grow at
very low density or grow in soft agar. The siSp1-
transfectants displayed obviously fewer and smaller
colonies than the siNC-transfectants, as shown by a
significant reduction in both the size and the number
of colonies (Figure 5A and B). In addition, knockdown
of Sp1 significantly suppressed the capacity of NPC
cells to grow in soft agar (Figure 5C and D). These re-
sults indicated that Sp1 silencing exerted a suppres-
sive role on the colony formation and anchorage-
independent growth of NPC cells.
Sp1 silencing inhibited sphere formation and impaired
the expressions of stem cell markers in NPC cells
Stem cells can be expanded as sphere-like cellular ag-
gregates in the sphere medium containing EGF and
bFGF. To further determine the role of Sp1 silencing in
the stem-cell like phenotype of NPC cells, sphere for-
mation potential was monitored. CNE2 cells transfected
with the indicated siRNA duplexes were cultivated in
the sphere medium for 7 days. The sphere formation
number was significantly lower in Sp1 silenced CNE2
cells (Figure 6A and B), suggesting knockdown of Sp1
may suppress the stem-cell like phenotype in CNE2
cells. Bmi1, c-Myc, KLF4, SOX2, NANOG and OCT4
are the key stem cell transcription factors (SCTFs).
ABCG2, an ABC transporter member, is associated with
the formation of side population and stem/progenitor
features in nasopharyngeal carcinoma [38]. We there-
fore determined whether knockdown of Sp1-suppressed
the stem-cell like phenotype was associated with
changes in these molecules. Bmi1, c-Myc, KLF4 and
ABCG2 were all decreased in Sp1-knockdown CNE2,
HNE1 and HK1 cells (Figure 6C). In contrast, OCT4
and SOX2 was unaffected by Sp1 knockdown, indicating
down-regulation of Sp1 suppressed the stem-cell like
phenotype, depending on the reduced expression of
Bmi1, c-Myc, KLF4, and ABCG2, but not OCT4 and
SOX2 (data not shown).
Taken together, our data suggest that Sp1 was enriched
in NPC cell lines as well as tissues and are highly corre-
lated with the NPC progression. Down-regulation of Sp1
may induce the expression of p27 and p21, as well as the
expressions of the critical SCTFs, resulting in the sup-
pression of cell proliferation, clonogenicity, anchorage-
independent growth and the stem-cell like phenotype in
NPC cells. These findings demonstrated the potential
use of Sp1 inhibitor in the clinical therapy of nasopha-
ryngeal carcinoma.
Figure 3 Both impaired Sp1 activity and expression suppressed the cell viability of NPC cells. (A) Inhibition of Sp1 activity by MITA
treatment decreased the cell viability of CNE2 and HNE1 cells. Twenty-four hours after seeding in 96-well plates, CNE2 and HNE1 cells were
treated with 100 nM MITA. The cell viability was determined by MTT assay at the indicated times. ** P < 0.01 and *** P < 0.001. (B) Sp1 was
completely abolished in CNE2 and HNE1 cells. After transfection with siSp1-1#, siSp1-2# or siNC for 72 h, cells were subjected to Western blot
analysis for Sp1. GAPDH was used as an internal control. (C) Silencing of Sp1 impaired the cell viability of CNE2 and HNE1 cells. After transfection
with siSp1-1#, siSp1-2# or siNC for 48 h, CNE2 and HNE1 cells were seeded into 96-well plates (2000/well) and incubated for the indicated times.
The cell viability was determined by MTT assay at the indicated times. *** P < 0.001.
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Although Sp1 has been investigated extensively in mul-
tiple types of cancers, the level of Sp1 in nasopharyngeal
carcinoma and molecular mechanisms by which Sp1
modulates the behavior of tumor cells remain elusive. In
the present study, we revealed that higher level of Sp1
correlates with advanced tumor stage in nasopharyngeal
carcinoma. Down-regulation of Sp1 suppressed cell
growth, the G1/S phase transition, clonogenicity and
anchorage-independent growth of NPC cells. Sp1 exert a
specific role on the expression of genes related to cell
proliferation and clonogenicity, such as p27, p21, Bmi1,c-Myc, KLF4 and ABCG2. Taken together, these results
suggest a fundamental role of Sp1 in the phenotypic
regulation of cancer cells, and implicate the potential ap-
plication of Sp1 in cancer therapy.
Sp1 has been extensively investigated in multiple can-
cers [26]. However, the significance of Sp1 in human
head and neck cancers, such as nasopharyngeal carcin-
oma, has never been explored. In the present study, the
pivotal roles of Sp1 in the cell proliferation, clonogeni-
city and anchorage-independent growth were confirmed
in CNE2 and HNE1 or HK1 cells. G1/S phase transition
is regulated by a balance of cyclins and cyclin-dependent
Figure 4 (See legend on next page.)
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Figure 4 Knockdown of Sp1 induces G1 phase arrest and up-regulates the expressions of p21 and p27. (A and B) Knockdown of Sp1
caused accumulation of G1 population. The representative images are shown in A and the percentage of cell distribution in G1/G0, S and G2/M
is illustrated in B. CNE2, HNE1 and HK1 cells were plated in 6-well culture plates and transfected with siSp1-1#, siSp1-2# or siNC for 72 h. Cells
were harvested, fixed, stained with propidium iodide and then analyzed for DNA content by flow cytometry. * P < 0.05, ** P < 0.01, *** P < 0.001.
(C and D) Knockdown of Sp1 enhanced the expressions of p27 and p21. CNE2, HNE1 and HK1 cells transfected with siSp1-1#, siSp1-2# or siNC
for 72 h were analyzed for the levels of cell cycle related genes by qRT-PCR (C) and Western blot (D). For (C), the mRNA level of the indicated
gene was normalized to β-actin. * P < 0.05, ** P < 0.01, *** P < 0.001. For (D), α-tubulin served as an internal control.
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phase entry, whereas cyclin-dependent kinase inhibitors
(e.g., p21 and p27) keep cells arrested in G1 phase. We
found knockdown of Sp1 significantly promoted the ex-
pressions of p21 and p27 in both CNE2 and HNE1 cells,
but had no obvious effect on the expressions of CDK4,
suggesting suppression of Sp1 promoted cell arrest in
G1 phase though the elevated levels of p27 and p21. Fur-
thermore, down-regulation of Sp1 may suppress the ac-
quisition of cancer stem cell phenotypes through the
reduced expressions of SCTFs, including Bmi1, c-Myc
and KLF4. Taken together, Sp1 promotes proliferation,
clonogenicity and anchorage-independent growth of
NPC cells.
In addition to being as an oncogene, Sp1 can also act as
a tumor suppressor in various types of cancer. Chuang
et al. reported that Sp1 overexpression suppressed the cell
growth and increased the sub-G1 fraction, caspase-3
cleavage, and annexin-V signal in HeLa and A549 cells.
When cells entered the mitotic stage, Sp1 overexpression
could induce p53-dependent apoptosis through affecting
mitotic chromatin packaging. Moreover, Hsu reportedFigure 5 Knockdown of Sp1 suppressed the clonogenicity and ancho
transfected with either siSp1-1#, siSp1-2# or siNC were grow at low density
with 5% FBS) in six-well plates for 14 days. For (A and B) Colonies were
methanol, and then were photographed and counted. All visible colonie
bigger than 100 μm were counted. ** P < 0.01, *** P < 0.001.that the proportion of low Sp1 expression in patients with
stage IV lung adenocarcinoma was higher than that in pa-
tients with stages I and II of lung adenocarcinoma. Sp1
negatively correlated with poor prognosis. Sp1 level accu-
mulated strongly in early stage and was required for lung
tumor growth, but it was declined in late stage and sup-
pressed metastasis through inducing E-cadherin expres-
sion. Therefore, the role of Sp1 in tumor development is
paradox and variable, largely depending on the cellular
context.
We previously reported that Sp1 activates the transcrip-
tion of Bmi1 and CENPH in nasopharyngeal carcinoma
[32,33]. Both Bmi1 and CENPH are oncogenes which are
elevated in various malignancies originating in the breast,
esophagus and nasopharynx [39-41]. Higher levels of
Bmi1 and CENPH are correlated with an advanced stage
and/or unfavorable prognosis. Bmi1, a member of the
polycomb group, promotes tumor progression by inhibit-
ing the transcription of tumor suppressors, such as p53
[42], p21 [43], INK4a and p19Arf [44]. CENPH, a basic
component of the constitutive centromere-associated net-
work, induces continuous chromosome instability duringrage-independent growth of NPC cells. CNE2 and HNE1 cells
for 10 days (A and B) or were plated onto 0.55% base agar (in RPMI
fixed with methanol and stained with 0.1% crystal violet in 20%
s were quantified. For (C and D), the colonies with the diameter
Figure 6 Knockdown of Sp1 suppressed the sphere formation and the expressions of stem cell markers of NPC cells. (A and B)
Knockdown of Sp1 repressed the sphere formation of CNE2 cells. CNE2 cells transfected with either siSp1-1#, siSp1-2# or siNC were grown in
tumor sphere medium for 7 days. Colonies were photographed at 200× magnification and were counted at 40× magnification. *** P < 0.001.
(C) The effect of Sp1 knockdown on the expressions of stem cell transcription factors. CNE2 and HNE1 cells transfected with siSp1-1#, siSp1-2# or
siNC for 72 h were analyzed for the levels of stem cell transcription factors by qRT-PCR. The expression level of the indicated gene was normalized
to β-actin. * P < 0.05, ** P < 0.01, *** P < 0.001.
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http://www.translational-medicine.com/content/12/1/222mitosis, which is found in the earliest stages of tumorigen-
esis [39]. Therefore, the cancer-promoting role of Sp1
may also be mediated by transcriptional activation of its
downstream genes, such as Bmi1 and CENPH.
MITA, an aureolic acid-type polyketide isolated from
streptomyces, specifically inhibits binding of Sp1 to GC-
rich DNA and thus suppressed the Sp1-targeted genes
mediating proliferation, angiogenesis, invasion and me-
tastasis [45]. It has been used in the treatment of various
malignancies, including testicular carcinoma [46], osteo-
lytic myelomatosis [47], pancreatic cancer [48]. However,
the role of MITA in NPC has never been explored. In
this study, MITA was found to significantly repress the
cell viability of both CNE2 and HNE1 cells, indicating
Sp1 may be the potential target in the clinical therapy of
nasopharyngeal carcinoma.
In summary, we investigated the expression level and
potential role of Sp1 in nasopharyngeal carcinoma and
its underlying mechanisms. Our data revealed thathigher level of Sp1 may play important role in the devel-
opment of nasopharyngeal carcinoma and highlighted
the potential use of Sp1 inhibitor in the clinical therapy
of NPC.
Conclusions
In the present study, we found the level of Sp1 was ele-
vated in cancerous than in normal primary NPECs, and
was higher in NPC tissues with advanced clinical stage
than that with early clinical stage. Either inhibition of
Sp1 activity by mithramycin A, the FDA-approved che-
motherapeutic anticancer drug or knockdown of Sp1 by
siRNA duplex suppressed the growth of NPC cells. Fur-
thermore, we demonstrated that silencing of Sp1 inhibited
cell proliferation, clonogenicity, anchorage-independent
growth and the stem-cell like phenotype of NPC cells
through inducing the expression of p27 and p21, and
through impairing the expressions of SCTFs, including
Bmi1, c-Myc, KLF4, NANOG and OCT4 in NPC cells.
Zhang et al. Journal of Translational Medicine 2014, 12:222 Page 11 of 12
http://www.translational-medicine.com/content/12/1/222These findings highlight the significance of Sp1 down-
regulation in suppressing cell proliferation, clonogenicity,
anchorage-independent growth and the stem-cell like
phenotype, implicating Sp1 as an attractive candidate for
NPC therapy.
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